Literature DB >> 49747

Return of spermatogenesis after stopping cyclophosphamide therapy.

J D Buchanan, K F Fairley, J U Barrie.   

Abstract

A follow-up of twenty-six male patients with azoospermia after stopping cyclophosphamide treatment showed a return of spermatogenesis in twelve patients within 15-49 months (mean 31 months). In one patient spermatogenesis returned despite 34 months of treatment with 100 mg. of cyclophosphamide daily. The period of follow-up after stopping cyclophosphamide therapy varied from 5 months to 4 years. After 6 months on cyclophosphamide all patients remained azoospermic while taking the drug. Return of spermatogenesis was not significantly associated with age, duration of cyclophosphamide therapy, total dose, or time of follow-up after stopping treatment; however, the number of patients in the study was small.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 49747     DOI: 10.1016/s0140-6736(75)90059-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group.

Authors:  Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 2.  [Drug treatment of dermatological disorders. Aspects to consider from an andrological perspective].

Authors:  S Grunewald; U Paasch
Journal:  Hautarzt       Date:  2015-12       Impact factor: 0.751

3.  Treatment of childhood cancer: effects on the gonads.

Authors: 
Journal:  Br Med J       Date:  1978-09-16

4.  A comparison of the antifertility effects of alkylating agents and vinca alkaloids in male rats.

Authors:  R A Cooke; A Nikles; H P Roeser
Journal:  Br J Pharmacol       Date:  1978-08       Impact factor: 8.739

5.  Gonadal function after combination chemotherapy for Hodgkin's disease in childhood.

Authors:  E Whitehead; S M Shalet; P H Jones; C G Beardwell; D P Deakin
Journal:  Arch Dis Child       Date:  1982-04       Impact factor: 3.791

6.  Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study.

Authors:  R Bogdanović; M Banićević; A Cvorić
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

7.  The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma.

Authors:  Irene A Burger; Hebert Alberto Vargas; Debra A Goldman; Mithat Gonen; Anita Kumar; Andrew D Zelenetz; Heiko Schöder; Hedvig Hricak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

Review 8.  Male gonadal toxicity.

Authors:  Marvin L Meistrich
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

9.  D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons.

Authors:  R W Lewis; K J Dowling; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

10.  Long term effects of cyclophosphamide on testicular function.

Authors:  A R Watson; C P Rance; J Bain
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.